Try our Advanced Search for more refined results
KBC Asset Management NV et al v. Aegerion Pharmaceuticals, Inc. et al
Case Number:
1:14-cv-10105
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Block & Leviton
- Fisher Potter
- Hogan Lovells
- Hutchings Barsamian
- Motley Rice
- Nutter McClennen
- Robbins Geller
- Ropes & Gray
Companies
Sectors & Industries:
-
December 07, 2017
Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement
A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.
-
December 05, 2016
Aegerion To Pay Investors $22M In Juxtapid Marketing Row
Aegerion Pharmaceuticals Inc. on Monday said it has agreed to pay $22.25 million to settle an investor class action in Massachusetts federal court alleging the biopharmaceutical company misled shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.
-
January 16, 2014
Aegerion Hit With Shareholder Suit Over Juxtapid Labeling
Aegerion Pharmaceuticals Inc. was hit with a proposed class action in Massachusetts federal court Wednesday accusing the biopharmaceutical company of misleading shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.